Table 2.

Virological, biochemical and serologic outcomes after long-term treatment in both entecavir and lamivudine arms n (%)

	ETV	LAM ± ADV	P-value
n	19	23
HBV DNA < 1000 IU/mL	18 (94.74)	22 (95.65)	0.8897
HBV DNA < 60 IU/mL	10/13 (76.92)	11/16 (68.75)	0.6243
ALT ≤ 1 × upper limit of normal	18 (94.74)	17 (73.91)	0.0715
HBeAg loss/HBeAg positive at baseline	6/13 (46.15)	10/14 (71.43)	0.1817
HBe seroconversion/HBeAg positivity at baseline	5/13 (38.46)	6/14 (42.86)	0.8163
HBsAg loss	0 (0)	0 (0)	-

ETV: Entecavir; LAM: Lamivudine; ADV: Adefovir; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen.